Polypeptide specifically bound on surface of hepatoma carcinoma cell

Abstract

The invention discloses a polypeptide specifically bound on the surface of a hepatoma carcinoma cell. A polypeptide fragment is screened out from a phage display random dodecapeptide library, and the amino acid sequence of the polypeptide fragment is LWDMSTPHRPLT. The polypeptide sequence bound with the hepatoma carcinoma cells is screened out by use of the phage polypeptide display technology; the affinity of phage clones and the hepatoma carcinoma cells is identified by virtue of ELISA, and 8 phage clones are obtained; 4 polypeptide sequences are obtained by sequencing, and the shared amino acid sequence of the4 polypeptide sequences is L(H)***S(T)*P(H)H(S)*P(L)LT(L); the targeting result of further identifying the positive phage clones by use of cell immunofluorescence indicates that the positive phage clone is capable of specific binding with the hepatoma carcinoma cell; the screened-out hepatoma carcinoma cell specific polypeptide provides experimental basis for early diagnosis of the liver cancer, the targeting transport of an anti-tumor drug and the development of a targeting oligopeptide drug.

Description

technical field [0001] The invention relates to the field of biotechnology, and relates to screening tumor tissue-specific binding peptides, in particular to a polypeptide (sequence) specifically binding to the surface of liver cancer cells. Background technique [0002] Liver cancer (Hepatocarcinoma) is one of the common malignant tumors of the digestive tract. In China, liver cancer is a disease with high morbidity, high mortality and high treatment costs. my country is one of the high-incidence areas of liver cancer in the world, and its incidence rate of liver cancer is about 10 times that of Europe and the United States. In terms of mortality, liver cancer ranks second in the mortality rate of malignant tumors in my country, second only to lung cancer. About 500,000 people die of liver cancer every year, and the incidence and mortality have been on the rise. Because liver cancer may not have symptoms in the early and middle stages, most cancer patients are already at ...

AI Technical Summary

Problems solved by technology

However, due to the lack of specific, cheap and convenient early diagnosis methods for liver cancer at present, the early detection rate of liver cancer is still very low, and the mortality rate of patients is still high.

Images